Publications

Skip to content

Publications

Explore Flatiron-authored research

Analysis of real-world progression and insufficient response variables and related endpoints among patients with non-Hodgkin lymphoma

Advances in Therapy

Richey M, Fullerton C, Zhang Q, et al

March 2025

publication-summary-analysis-of-real-world-progression-with-insufficient-response-variables-and-related-endpoints-among-patients-with-non-hodgkin-lymphoma

1,800 publications—and counting

To date, over 1,800 publications—authored by either Flatiron or our partners—have used Flatiron’s real-world data

Explore a list of all publications

See the impact of our data

Database Characterization Guide

An overview of Flatiron Health EHR-derived US data for journal reviewers and readers to better understand the data used in publications

Review our guide

Explore our summaries of Flatiron-authored research

Disease area

Acute myeloid leukemia

Breast cancer

Chronic lymphocytic leukemia

Colorectal cancer

Diffuse large B-Cell lymphoma

Gastric/Esophageal cancer

Head and neck cancer

Hepatocellular carcinoma

Melanoma

Metastatic breast cancer

Multiple myeloma

Non-small cell lung cancer

Ovarian cancer

Pancreatic cancer

Prostate cancer

Renal cell carcinoma

Small cell lung cancer

Tumor agnostic

Urothelial cell carcinoma

Topics

Comparative effectiveness

Drug discovery

HTA and market access

Health equity

Label expansion

Machine learning

Methodology

Prospective study

Quality improvement

Quality reporting

Regulatory

Resistance ID

Treatment patterns

Unmet need

Showing 9 of 0 results

ESMO Open
September 2025
Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practice
Rugo H, Layman R, Lynce F, et al.
World Conference on Lung Cancer
August 2025
A novel predictive gene signature for liver metastasis (LM) in NSCLC using a comprehensive linked Clinical-Molecular Database
Papillon-Cavanagh S, Snider J, Murphy E, Bouzit L, Cho-Phan C, Zimmerman Savill K M.
World Conference on Lung Cancer
August 2025
Real-world treatment patterns and clinical outcomes in patients with metastatic neuroendocrine neoplasms of the lung (NEN-L)
Zu K, Vaidya R, Cho-Phan C, Hu H.
World Conference on Lung Cancer
August 2025
Real-world biomarker testing and treatment initiation in patients with resected early-stage NSCLC (eNSCLC) in the US and UK
Rinaldi C, Halloran S, Pittel H, et al.
World Conference on Lung Cancer
August 2025
Real-world outcomes of prophylactic cranial irradiation in extensive-stage small cell lung cancer treated with first-line immunotherapy and platinum-etoposide
Reiss S, Rinaldi C, Castellanos E, Li X.
World Conference on Lung Cancer
August 2025
Real-world survival outcomes in non–small cell lung cancer: Insights from UK EHR-derived data
Samani A, Zhang Q, Sujenthiran S, van Bömmel-Wegmann S, Adamson B.
World Conference on Lung Cancer
August 2025
Disease burden and rwPFS as a surrogate endpoint for rwOS in NTRK+ NSCLC and other advanced/metastatic solid tumor
Flores Avile C, Su I-H, Huang P-C, Cho-Phan C, Camidge R, Yuan Y.
World Conference on Lung Cancer
August 2025
Evolving treatment patterns in early-stage non-small cell lung cancer in the US
Gray J E, Thoele K, Gilligan A M, et al.
World Conference on Lung Cancer
August 2025
Real-world treatment patterns in ES-SCLC highlight continued unmet medical need in the era of new therapies: ESSENCE Study
Halmos B, Anand S, Juneau P, et al.

Reimagining the infrastructure of cancer care

Resources
Publications
Company
Media
Careers
Contact Us

Clinical Research
Real-World Evidence
Point of Care

Legal, Privacy, and Compliance
Data Confidentiality Commitments
Cookie Settings
© FLATIRON HEALTH® 2025